Expert hematologist-oncologists Thomas Leblanc, MD, and Bhumika Patel, MD, review clinical data behind the long-term use of tagraxofusp and share their own experience.
EP. 1: An Overview on Blastic Plasmacytoid Dendritic Cell Neoplasm and Tagraxofusp Therapy
Expert hematologist-oncologists share their perspective on the broad diagnosis and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
EP. 2: Long-Term Efficacy Data of Tagraxofusp in the 1L Management of BPDCN
Centering discussion on a recent study, experts Thomas Leblanc, MD, and Bhumika Patel, MD, reflect on long-term data with tagraxofusp in BPDCN.
EP. 3: Tagraxofusp in BPDCN: Optimizing the Management of Adverse Events
Comprehensive discussion on the management of adverse events associated with tagraxofusp and how BPDCN care can be optimized in the setting of academic centers.
EP. 4: BPDCN Management: Tagraxofusp as a Bridge to Stem Cell Transplant
A brief review of the role of tagraxofusp as bridging therapy to stem cell transplant in patients diagnosed with blastic plasmacytoid dendritic cell neoplasm.
EP. 5: Addressing Myelosuppression While Managing BPDCN With Tagraxofusp
Before closing out their review of adverse events associated with tagraxofusp, Thomas Leblanc, MD, and Bhumika Patel, MD, reflect on the identification and management of myelosuppression.
EP. 6: Tagraxofusp in BPDCN: Practical Advice and Future Directions in Care
After sharing key takeaways on the management of BPDCN, expert hematologist-oncologists highlight unmet needs and forecast evolutions in care.
EP. 7: Recap: Experts Review Tagraxofusp and Long-term Benefits in Blastic Plasmacytoid Dendritic Cell Neoplasm
Expert hematologist-oncologists review the clinical data on the long-term use of tagraxofusp and share their real-world experiences.
2 Commerce Drive Cranbury, NJ 08512